Mutagenicity of hydroxyurea in lymphocytes from patients with sickle cell disease

André Salim Khayat, Adriana Costa Guimarães, Plínio Cerqueira Cardoso, Patrícia Danielle Lima de Lima, Marcelo de Oliveira Bahia, Lusânia M. Greggi Antunes, Rommel Rodríguez Burbano
2004 Genetics and Molecular Biology  
Hydroxyurea is commonly used in the treatment of myeloproliferative diseases and in patients with sickle cell disease (SCD). The use of this antineoplastic agent in patients with SCD is justified because of the drug's ability to increase fetal hemoglobin levels, thereby decreasing the severity of SCD. However, high doses or prolonged treatment with hydroxyurea can be cytotoxic or genotoxic for these patients, with an increased risk of developing acute leukemia. This danger can be avoided by
more » ... toring the lymphocytes of patients treated with hydroxyurea. Cytogenetic tests are important endpoints for monitoring the physiological effects of physical and chemical agents, including drugs. In this work, we assessed the genotoxicity of hydroxyurea in short-term cultures of lymphocytes from SCD patients. Hydroxyurea was not cytotoxic or genotoxic at the concentrations tested in the G2 phase of the cell cycle. These results support the use of hydroxyurea in the treatment of SCD, although further work is necessary to understand the effects of this drug in vivo. Peripheral blood samples were collected from eight patients (five men and three women) by venipuncture. The
doi:10.1590/s1415-47572004000100019 fatcat:jmqf7xql3ffqdf62jv2e2tvwma